The efficacy and safety of Salmeterol/Fluticasone Propionate 50/500ug BD vs Ipratropium/Albuterol 36/206ug QID in Chinese patients with moderate-to-severe COPD: A 12-week, multicentre, randomized, open-label, active-controlled, paralled-group study

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipratropium-bromide/salbutamol (Primary) ; Salmeterol/fluticasone propionate (Primary)
Indications Chronic obstructive pulmonary disease
Focus Biomarker; Therapeutic Use

Most Recent Events

13 Apr 2012 Official title amended as reported by Chinese Clinical Trial Register.
29 Nov 2010 New trial record
18 Nov 2010 Additional lead trial centres identified as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight